Wall Street analysts expect that MEDNAX Inc (NYSE:MD) will announce earnings per share (EPS) of $0.84 for the current quarter, Zacks Investment Research reports. Eight analysts have provided estimates for MEDNAX’s earnings, with the highest EPS estimate coming in at $0.87 and the lowest estimate coming in at $0.80. MEDNAX posted earnings per share of $0.87 during the same quarter last year, which indicates a negative year-over-year growth rate of 3.4%. The company is scheduled to report its next quarterly earnings results on Thursday, November 7th.
On average, analysts expect that MEDNAX will report full-year earnings of $3.04 per share for the current fiscal year, with EPS estimates ranging from $2.97 to $3.13. For the next financial year, analysts anticipate that the business will report earnings of $3.27 per share, with EPS estimates ranging from $3.03 to $3.54. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow MEDNAX.
MEDNAX (NYSE:MD) last posted its earnings results on Thursday, August 1st. The company reported $0.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.11. The firm had revenue of $868.31 million during the quarter, compared to analyst estimates of $868.71 million. MEDNAX had a negative net margin of 3.53% and a positive return on equity of 9.34%. MEDNAX’s revenue was up .4% on a year-over-year basis. During the same period in the previous year, the business posted $1.07 EPS.
In other MEDNAX news, Director Michael Fernandez bought 122,409 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were acquired at an average cost of $21.35 per share, for a total transaction of $2,613,432.15. Following the acquisition, the director now directly owns 350,288 shares of the company’s stock, valued at $7,478,648.80. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Md Pascal J. Goldschmidt sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $20.81, for a total transaction of $104,050.00. Following the completion of the sale, the director now owns 15,821 shares in the company, valued at $329,235.01. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. D. E. Shaw & Co. Inc. raised its holdings in shares of MEDNAX by 20.7% during the second quarter. D. E. Shaw & Co. Inc. now owns 3,001,827 shares of the company’s stock valued at $75,736,000 after acquiring an additional 515,286 shares during the period. P2 Capital Partners LLC raised its holdings in shares of MEDNAX by 96.9% during the second quarter. P2 Capital Partners LLC now owns 2,750,000 shares of the company’s stock valued at $69,383,000 after acquiring an additional 1,353,111 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of MEDNAX by 17.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,615,192 shares of the company’s stock valued at $86,301,000 after acquiring an additional 381,394 shares during the period. Nordea Investment Management AB raised its holdings in shares of MEDNAX by 41.5% during the first quarter. Nordea Investment Management AB now owns 2,411,506 shares of the company’s stock valued at $65,521,000 after acquiring an additional 707,038 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of MEDNAX by 86.2% during the second quarter. AQR Capital Management LLC now owns 1,754,829 shares of the company’s stock valued at $43,327,000 after acquiring an additional 812,425 shares during the period. Institutional investors and hedge funds own 92.30% of the company’s stock.
MEDNAX stock opened at $23.88 on Friday. The company has a quick ratio of 2.23, a current ratio of 2.23 and a debt-to-equity ratio of 0.79. The firm has a 50-day moving average price of $21.95 and a two-hundred day moving average price of $26.03. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of 6.80, a PEG ratio of 0.89 and a beta of 0.73. MEDNAX has a 52-week low of $19.93 and a 52-week high of $48.77.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Further Reading: The limitations of an equal weight rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.